thyroid

08.02.2023 • News

Amgen-Horizon Deal under Intense Scrutiny

Amgen’s proposed acquisition of Horizon Therapeutics for $28.7 billion, including debt, would be the largest healthcare deal since AstraZeneca’s $39 billion purchase of Alexion in 2021, if it goes ahead. As such, it is under intense scrutiny.

30.11.2017 • News

UK Watchdog Finds Concordia Guilty of Market Abuse

29.07.2015 • News

Genzyme to Acquire AstraZeneca Rare Disease Therapy

Top-Feature

Bio-Rad Laboratories

Dual‑Targeting Breakthroughs: Advancements in Bispecific Antibody Development

CHEManager International c/o Wiley-VCH GmbH

Digitalization in the Chemical Industry

Interview

Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.